Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 1000+ Conferences, 1000+ Symposiums and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.
Explore and learn more about Conference Series: World’s leading Event Organizer
Subarachnoid hemorrhage is a type of stroke which occurs when there is bleeding in the subarachnoid space around the brain. The incidence in the UK is approximately 8 per 100,000population per year (0.008%). The commonest cause of SAH is rupture of a cerebral aneurysm other causes include arteriovenous malformations, tumors, trauma and non-aneurysmalperimesencephalic hemorrhage. This tutorial addresses the management of spontaneous aneurysmal SAH.
The anesthetist may be involved in the management of patients with SAH at several stages initial resuscitation and stabilization, therapeutic management in the ICU and providing anesthesia preoperatively for aneurismal occlusion.
The prognosis is poor with an overall case fatality of 50%however early treatment has been shown to improve outcome and it is therefore imperative that the anesthetist is familiar with all aspects of the condition and up to date with the latest evidence based management. The mainstays of treatment are occlusion of the aneurysm by endovascular coiling or surgical clipping, and prevention of cerebral ischemia.
A Subarachnoid Hemorrhage occurs when a blood vessel either on or inside the brain suddenly begins to leak blood. This blood settles into a space between the surface of the brain and the skull called the subarachnoid space. The leaked blood may also settle into other areas of the brain, but it is the blood in this subarachnoid space that causes SAH's unique problems and risks.
More symptoms such as:
• Speech Changes
• Drowsiness (sleepiness)
• Loss of consciousness
SAH accounts for 5-15% of all strokes and has an overall case fatality of around 50% with a trend towards gradual improvement. This includes the 10-15% of patients who die before reaching hospital the rest dying within the first 3 weeks secondary to re-bleeding and cerebral vasospasm. Of those who survive, one third remains moderately to severely disable. The rate of rebleed is 2-4% within the first 24 hours and 15-20% within the first 2 weeks if left unoccluded. The main predictors of mortality and dependence are impaired level of consciousness on presentation, advanced age and a large volume of blood on initial CT scan.
Omics group is conducting International Conference on Brain Disorders and Therapeutics which is going to be held in London, UK on August 24-26, 2015.
About OMICS Group:
OMICS International is an integration of Open Access publications and worldwideInternational Scientific conferences and events. OMICS Group is a pioneer and leading Science event organizer, which publishes around 400 peer reviewed open access journals in all aspects of science, health, and technology. OMICS Group world class International conference organizer successfully coordinates 300 International conferences across the globe to accelerate the knowledge transfer through debates, round table discussions, poster presentations, workshops, symposia and exhibitions.
We are actively involved in conducting International Conferences across various continents such as Europe, USA (Baltimore, Philadelphia, Las Vegas, and San Antonio), China, Dubai, UK and other parts of the globe.
12th International conference on neurovascular events after subarachnoid hemorrhage
Joint EANS annual meeting-4th world ICH conference
NINDS Conference on Intracerebral Hemorrhage: Neurosurgeons at the Forefront
XXIII European Stroke Conference,
RELEVANT SOCIETY AND ASSOCIATIONS
Neurocritical care society
This page will be updated regularly.
This page was last updated on 10th Oct, 2014
1-702-508-5200 Ext:8031, 8041
1-702-508-5200 Ext:8045, 8047
Immunology & Microbiology Conferences
Nursing and Healthcare Conferences
Clinical and Biochemistry Conferences
1-702-508-5200 Ext:8031, 8037
Material Science Conferences
Genetics & Mol Biology Conferences
Media Partners | Advertising